Kilitch Drugs (India) (NSE:KILITCH) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:KILITCH Kilitch Drugs (India) Ltd NSE:KILITCH
84 GF Score
Price ₹186.59
GF Value ₹227.72
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Kilitch Drugs (India) Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Kilitch Drugs (India) Valuation Rank Related Terms

NSE:KILITCH
84GF Score
Kilitch Drugs (India) Ltd NSE:KILITCH
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?

Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued. The current stock price of ₹186.59 is trading 18.1% below its estimated GF Value™ of ₹227.72. GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.

Key valuation signals for NSE:KILITCH:

  • Valuation Rank:
  • GF Value™: ₹227.72 vs. price of ₹186.59 (18.1% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kilitch Drugs (India) Business Description

Other Exchanges 524500:India
Address Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
84GF Score

Get the complete analysis for NSE:KILITCH

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹186.59
Price
₹227.72
GF Value